Tonix Pharmaceuticals Publishes Research On High-Throughput Screening Assay For Neutralizing Antibodies Against SARS-CoV-2 Variants; Study Showcases Internal R&D Capabilities, Including NIH-Selected COVID-19 Vaccine And DoD/DTRA Awarded Anti-Viral Program
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has published research on a high-throughput screening assay for neutralizing antibodies against SARS-CoV-2 variants. The study highlights the company's internal R&D capabilities, including a COVID-19 vaccine selected by the NIH and an anti-viral program awarded by the DoD/DTRA.
August 06, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' publication of research on a high-throughput screening assay for neutralizing antibodies against SARS-CoV-2 variants showcases their R&D capabilities, including a COVID-19 vaccine selected by the NIH and an anti-viral program awarded by the DoD/DTRA.
The publication of this research highlights Tonix Pharmaceuticals' advanced R&D capabilities and their involvement in significant COVID-19 related projects. This positive development is likely to boost investor confidence and potentially increase the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100